Advanced Search

Journal of Traditional Chinese Medicine >

2026 , Vol. 46 >Issue 4: 951 - 960

DOI: https://doi.org/10.19852/j.cnki.jtcm.2026.04.015

Original Articles

Effect of Jinlong capsule (金龙胶囊) on the survival of patients with hepatocellular carcinoma: a propensity score matching study

  • SHI Ke ,
  • ZHANG Yi ,
  • SUN lina ,
  • WANG Xianbo ,
  • FENG Ying
Expand
  • Center of integrative medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 10015, China

Received date: 2025-02-12

  Accepted date: 2025-07-24

  Online published: 2026-08-08

Supported by

Capital's Funds for Health Mprovement and Research: a Study on the Therapeutic Effect of Shugan Jianpi Huoxue Prescription on High Risk Population of Liver Cancer with Liver Cirrhosis in Compensatory Period and the Key Technology of Early Warning of Liver Cancer(2024-1-2173);Beijing Municipal Natural Science Foundation: a Study on the Mechanism of Fuzheng Jiedu Xiaoji Formula Inhibiting Signal Transducer and Activator of Transcription 3 Pathway to Improve the Efficacy of Dual-target Chimeric Cntigen Receptor T-cell Based on Hepatocellular Carcinoma Organoids(7232272);National Natural Science Foundation of China: a Study on the Jiedu Liangxue Jianpi Decoction Inhibits Acute Liver Failure by Targeting Neutrophil Extracellular Traps Formation Induced by Wilms' Tumor 1-associating Protein/N6-methyladenosine-ras Homolog Family Member A/Macrophage-1 Antigen Axis(82474419);a Study on the Effect of Fuzheng Jidu Xiaoji Prescription on Regulating Pyruvate Kinase M2 Lactate Modification to Enhance the Efficacy of Chimeric Cntigen Receptor T-cell Cells Based on Hepatocellular Carcinoma Organoid Symbiosis System(82474426);Beijing High-level Innovation and Entrepreneurship Talent Support Programein-young Backbone Talent Projects: Evaluation of the Huoxue Jianpi Formula for Preventing Carcinogenesis in Hepatitis B-related Cirrhosis and the Establishment of an Early Warning System(G202532309)

Fold

Abstract

OBJECTIVE: To evaluate the impact of Jinlong capsule (金龙胶囊) on the overall survival (OS) rates of patients with hepatocellular carcinoma (HCC) at various stages of the disease.

METHODS: A total of 799 patients diagnosed with HCC between January 2016 and December 2019 were enrolled. The three-year OS rate of the Jinlong group (n = 144) was compared with that of the control group (n = 655). To minimize potential bias, propensity score matching (PSM) was applied. Kaplan-Meier survival analysis was used to assess the OS rates of different subgroups, with statistical significance determined by the log-rank test.

RESULTS: The Cox regression model revealed that Jinlong treatment was independently associated with an improved three-year OS. The Jinlong group had a significantly higher OS rate than the control group, with an adjusted hazard ratio of 0.48 (95% confidence interval: 0.38-0.60; P <0.001). After applying PSM at a 1∶2 ratio, 140 patients were included in the Jinlong group and 280 in the control group. The OS rate for the Jinlong group was substantially longer than that for the control group (65.7% vs48.2%, P <0.0001). Additionally, the aHR for Jinlong use showed a dose-response effect: 0.36 for 3-12 months, 0.28 for 12-24 months, and 0.09 for > 24 months of use. Compared to the control treatment, Jinlong treatment consistently reduced the risk of death within three years, of most subgroups.

CONCLUSIONS: Jinlong treatment significantly improved the three-year survival rate of patients with HCC. These findings provide a foundation for further studies into the effectiveness of Jinlong capsule in the treatment of HCC.

Key words： Chinese patent medicine; liver cancer; propensity score matching, prognosis; Jinlong capsule; cohort studies

Cite this article

SHI Ke , ZHANG Yi , SUN lina , WANG Xianbo , FENG Ying . Effect of Jinlong capsule (金龙胶囊) on the survival of patients with hepatocellular carcinoma: a propensity score matching study[J]. Journal of Traditional Chinese Medicine, 2026 , 46(4) : 951 -960 . DOI: 10.19852/j.cnki.jtcm.2026.04.015

References

1. Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol 2022; 77: 1598-606.
2. Yang J, Hainaut P, Gores G, Amadou A, Plymoth A, Roberts L. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019; 16: 589-604.
3. Sung H, Ferlay J, Siegel R, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-49.
4. Singal A, Kanwal F, Llovet J. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol 2023; 20: 864-84.
5. Ganesan P, Kulik LM. Hepatocellular carcinoma: new developments. Clin Liver Dis 2023; 27: 85-102.
6. Nevola R, Ruocco R, Criscuolo L, et al. Predictors of early and late hepatocellular carcinoma recurrence. World J Gastroenterol 2023; 29: 1243-60.
7. Xu W, Li R, Liu F. Novel prognostic nomograms for predicting early and late recurrence of hepatocellular carcinoma after curative hepatectomy. Cancer Manag Res 2020; 12: 1693-712.
8. Liu Y, Wu J, Hao H. Antitumor immunostimulatory activity of the Traditional Chinese Medicine polysaccharide on hepatocellular carcinoma. Front Immunol 2024; 15: 1369110.
9. Li S, Gao Q, Li Y, Zhang Y, Chen X. Efficacy and safety of Yangxiao Fukang granule in the treatment of stage Ⅲ hepatitis B related liver cancer: study protocol for a randomized controlled trial. J Tradit Chin Med 2025; 45: 1127-34.
10. Zhu L, Li S, Zheng W, Ni W, Cai M, Liu H. Targeted modulation of gut microbiota by Traditional Chinese Medicine and natural products for liver disease therapy. Front Immunol 2023; 14: 1086078.
11. Liu X, Li M, Wang X, et al. Effects of adjuvant Traditional Chinese Medicine therapy on long-term survival in patients with hepatocellular carcinoma. Phytomedicine 2019; 62: 152930.
12. Liao Y, Kung P, Wang Y, Chu Y, Kao S, Tsai W. Effects and relative factors of adjunctive Chinese medicine therapy on survival of hepatocellular carcinoma patients: a retrospective cohort study in Taiwan. Integr Cancer Ther 2020; 19: 1534735420915275.
13. Tang K, Du S, Wang Q, Zhang Y, Song H. Traditional Chinese Medicine targeting cancer stem cells as an alternative treatment for hepatocellular carcinoma. J Integr Med 2020; 18: 196-202.
14. Wu G, Zhang L, Li T, Chen J, Yu G, Li J. Short-term effect of combined therapy with Jinlong capsule and transcatheter arterial chemoembolization on patients with primary hepatic carcinoma and its influence on serum osteopontin expression. Chin J Integr Med 2010; 16: 109-13.
15. Shi J, Zhang W, He L, et al. Jinlong capsule inhibits migration and invasion in human glioblastoma cells via the modulation of mTOR/ S6 signaling pathway. Drug Des Devel Ther 2019; 13: 1023-32.
16. Li D, Ni T, Tao L, et al. Jinlong Capsule (JLC) inhibits proliferation and induces apoptosis in human gastric cancer cells in vivo and in vitro. Biomed Pharmacother 2018; 107: 738-45.
17. Xu H, Wei W, Y M, Dong C. Efficacy and safety of Chinese patent medicine (Jinlong capsule) in the treatment of advanced hepatocellular carcinoma: a Meta-analysis. Biosci Rep 2020; 40: BSR20194019.
18. Omata M, Cheng A, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017; 11: 317-70.
19. Li C, Li F, Ye H, et al. Molecular quantification, a new strategy for quality control of Chinese patent medicine containing animal-derived crude drug: Qishe in Jinlong capsule as an example. J Pharm Biomed Anal 2022; 207: 114428.
20. Ruf A, Dirchwolf M, Freeman R. From child-pugh to MELD score and beyond: taking a walk down memory lane. Ann Hepatol 2022; 27: 100535.
21. Liang J, Hu Z, Zhan C, Wang Q. Using propensity score matching to balance the baseline characteristics. J Thorac Oncol 2021; 16: e45-6.
22. Kane L, Fang T, Galetta M, et al. Propensity score matching: a statistical method. Clin Spine Surg 2020; 33: 120-2.
23. Wang Y, Deng B. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev 2023; 42: 629-52.
24. Yuan H, Niu Q, Shang X, et al. Impact of Traditional Chinese Medicine on prognosis of patients with hepatocellular carcinoma: a retrospective cohort study. Integr Cancer Ther 2023; 22: 15347354231170536.
25. Wei L, Wang Z, Jing N, et al. Frontier progress of the combination of modern medicine and Traditional Chinese Medicine in the treatment of hepatocellular carcinoma. Chin Med 2022; 17: 90.
26. Jia S, Fu Y, Tao H. Trans-arterial chemoembolization combined with Jinlong capsule for advanced hepatocellular carcinoma: a PRISMA-compliant Meta-analysis in a Chinese population. Pharm Biol 2020; 58: 771-84.
27. Sun L, Fahey P, Zhu X, et al. A cohort study to examine the use of Chinese herbal medicine in combination with conventional therapies for patients with hepatocellular carcinoma in China. Integr Cancer Ther 2018; 17: 902-11.
28. Li Y, Hu J, Huang H, He Y. Effect of Jinlong capsule on proliferation and apoptosis of human pancreatic cancer cells BxPC-3. J Tradit Chin Med 2013; 33: 205-10.
29. Jin Y, Duan LX, Xu XL, et al. Mechanism of apoptosis induction in human hepatocellular carcinoma cells following treatment with a gecko peptides mixture. Biomed Rep 2016; 5: 73-8.
Options
Outlines

/

〈 〉